Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine C Roberts

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Vaccine|June 9, 2023
Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boostWoo Joo Kim, Christine C Roberts, Joon Young Song, et al.
The New England Journal of Medicine|September 15, 2021
Safety and Immunogenicity of an Anti-Zika Virus DNA VaccinePablo Tebas, Christine C Roberts, Kar Muthumani, et al.
The Journal of Infectious Diseases|March 21, 2019
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy VolunteersPablo Tebas, Kimberly A Kraynyak, Ami Patel, et al.
The Journal of Infectious Diseases|July 28, 2018
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid ImmunizationMarc-Antoine de La Vega, Jocelyne Piret, Bryan D Griffin, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 2, 2023
Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction deviceWoo Joo Kim, Christine C Roberts, Joon Young Song, et al.
Lancet (London, England)|September 10, 2017
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trialWarner K Huh, Elmar A Joura, Anna R Giuliano, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Vaccine|June 9, 2023
Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boostWoo Joo Kim, Christine C Roberts, Joon Young Song, et al.
The New England Journal of Medicine|September 15, 2021
Safety and Immunogenicity of an Anti-Zika Virus DNA VaccinePablo Tebas, Christine C Roberts, Kar Muthumani, et al.
The Journal of Infectious Diseases|March 21, 2019
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy VolunteersPablo Tebas, Kimberly A Kraynyak, Ami Patel, et al.
The Journal of Infectious Diseases|July 28, 2018
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid ImmunizationMarc-Antoine de La Vega, Jocelyne Piret, Bryan D Griffin, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 2, 2023
Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction deviceWoo Joo Kim, Christine C Roberts, Joon Young Song, et al.
Lancet (London, England)|September 10, 2017
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trialWarner K Huh, Elmar A Joura, Anna R Giuliano, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Pageof 3